Despite recent advances in the field of allogeneic hematopoietic cell transplantation (HCT), viral infections are still a major complication during the period of immune suppression that follows the procedure. Adoptive transfer of donor-derived virus specific cytotoxic T cells (VSTs) is a strategy to rapidly restore virus-specific immunity to prevent or treat viral diseases after HCT.
INTRODUCTION
Viral infections remain a leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). 1 The use of prophylactic pharmacotherapy is effective in reducing risk for some viral infections, but therapeutic options for breakthrough infections are complicated by toxicities and for many viral infections there are limited/no effective prophylactic or therapeutic pharmacotherapies. 2 T-cell reconstitution is a key requirement for effective antiviral control following HCT, and factors that influence the speed of T-cell recovery also impact the risk of viral infection in this period. 3 The use of donor lymphocyte infusions (DLI) derived from seropositive stem cell donors is an effective salvage therapy for viral infections in HCT recipients prior to T-cell recovery, but the risk of potentially severe Graft versus Host Disease (GVHD) is a concern. 4,5 Depletion of specific T cell subsets such as naïve T cells from the infused HCT product may preserve antiviral immunity while depleting alloreactive cells, 6 and it is also possible to deplete alloreactive populations from DLI products to produce antiviral activity in the absence of GVHD or to include a suicide gene as a safety switch in an alloreplete product. 7, 8 A more specific approach to expedite virus-specific T-cell reconstitution is adoptive transfer of donor-derived virus-specific T cells (VSTs) and this strategy has been successfully applied over the last two decades in many centers to prevent and treat viral infections. [9] [10] [11] [12] Development of VST therapy to broader applicability has been facilitated by several advances in immunobiology, including: (i) the knowledge of conserved T-cell epitopes for various pathogens, 13-16 (ii) improvements in ex vivo culture methodologies for the generation of T-cells and antigenpresenting cells [16] [17] [18] and (iii) rapid assays to evaluate the effector function of VSTs. 16 Here, we will summarize the methodologies used in generating donor-derived VSTs, review the results of clinical trials using VST therapies after HCT, and discuss how recent manufacturing For personal use only. on October 4, 2017. by guest www.bloodjournal.org From improvements to simplify the VST generation process and the use of third-party banks now allow testing of this strategy in later phase clinical trials.
GROUND RULES FOR T CELL MANUFACTURING

Antigen selection
The ex vivo generation and expansion of VSTs for clinical use requires: (i) a defined immunogenic antigen and (ii) an antigen-presenting cell (APC) that can effectively present antigen to the T-cells with appropriate co-stimulatory signals. Hence, for a given virus, it is important to know which viral antigens are immunodominant and induce protective T cells in vivo. For some latent viruses (e.g. CMV and EBV) the immunodominant antigens expressed at different stages of infection have been well defined, 13, 15 but for others such as adenovirus, HHV6 and BK virus the appropriate target antigens had to be identified to design adoptive immunotherapy studies. 16, 19, 20 This process has been simplified by the increasing availability of bioinformatic tools that enable the effective mapping of viral epitopes recognized by both CD4+ and CD8+ T cells.
Antigen Presentation
Defined immunogenic antigens must be presented utilizing an APC that expresses major histocompatibility complex (MHC) antigens to present virus antigen-derived peptides as well as co-stimulatory molecules sufficient to induce T cell activation and expansion. The choice of APC also depends on the type of viral antigen to be used and the proposed method of delivery.
Examples of antigens used to manufacture VSTs include whole virions, specific viral genes, whole proteins or peptides. APCs used include fibroblasts, dendritic cells (DCs), monocytes, B
cells and artificial K562 based cells. Specific examples include:
(i) Whole virus or viral lysate to expand VSTs. The use of the entire viral antigen enables the generation of a broad CD8+ as well as CD4+ T-cell response. CMV lysate or antigen have both For personal use only. on October 4, 2017. by guest www.bloodjournal.org From been used to infect fibroblasts or to pulse DCs to ex vivo expand CMV-specific T cells. 11, 12 Similarly, intial studies used B cells infected with the B95-8 laboratory strain of EBV to generate EBV-infected lymphoblastoid cell lines (LCLs), which are potent APCs, to ex vivo expand polyclonal and polyfunctional EBV-specific T-cells. 9, 21 However, the use of viral lysate or LCLs containing infectious virus makes it more challenging to transition an approach to late phase trials given the potential infection risk.
(ii) Whole proteins. In some cases a whole viral protein has been used. In this case the protein must be universally expressed and immunogenic. Examples include the use of the CMVpp65 protein to manufacture of CMV-specific T cells 22 or the use of the EBNA-1 protein to expand EBNA-1 specific T cells for EBV-associated post transplant lymphoproliferative disease (PTLD). 23
(iii) Gene modified APC (viral vectors and plasmids).
Another approach is to genetically modify APCs with adenoviral (Ad) vectors encoding viral antigens such as CMVpp65, or EBV LMP2 to expand VSTs. Ad vectors (with or without a transgene) also effectively expand T cells recognizing the adenoviral virion proteins hexon and penton expressed by the vector itself.
Further, transduction of LCL with an Ad vector not only expands Ad hexon/penton-specific T cells but also expands T cells specific for the latent and early lytic cycle EBV proteins expressed by the LCL. 24 As an alternative to viral vectors, plasmids expressing viral antigens derived from multiple viruses have also been used to transfect DC to stimulate multi-virus specific T cells for clinical use. 25 (iv) Peptides and peptide mixtures. Several groups have explored the use of individual HLArestricted peptides/epitopes such as the A2-restricted CMVpp65 epitope NLV to stimulate VSTs. 26 Concerns with this approach are that targeting a single epitope will result in escape mutants and that it is restricted to patients with specific HLA types. However, the more recent availability of overlapping peptide pools or pepmixes where overlapping peptide libraries represent the entire protein sequences of the target viral antigens has provided a readily For personal use only. on October 4, 2017. by guest www.bloodjournal.org From available and GMP compliant source of viral antigen(s) validated in several preclinical and clinical studies. 16, 18, 20, 27, 28 Pepmixes are now the most widely used source of viral antigen in current clinical trials.
(v) Artificial APC. Autologous APCs may be limited, especially if large numbers of VSTs are required or to help priming of the virus-specific response in vitro (e.g. when the donor is seronegative) is required. Several groups have explored the use of artifical APCs. For example, a novel artifical antigen-presenting complex (KATpx) was developed for the expansion of virus specific T cells for clinical use. Using this approach, viral pepmixes were presented by APCs and these peptide loaded cells were cocultured with irradiated HLA-negative K562 cells genetically modified to express CD80, CD83, CD86, and 4-1BBL (K562cs) that provided complementary costimulation in trans to effectively stimuate and expand VSTs. 29 An alternative strategy to obtain larger numbers of APCs is to use the stem cell product as a source of cells for APC production. 30
Expansion strategies
The manufacture of VST products for clinical use requires the selection of VSTs and the exclusion of alloreactive T-cells using a GMP-compliant approach. Initial studies used complex methodologies requiring significant ex vivo expansion and in some cases cloning. 9, 12 In order to make VSTs more broadly available recent studies have focused on rapid manufacturing strategies including: (i) direct selection of donor-derived VSTs with multimers or gamma capture, and (ii) stimulation and brief ex vivo expansion of donor T-cells (Figure 1) . The advantage and disadvantages of each approach, as well of the use of third-party T cells, are summarized in Table 1 .
(i)
Ex vivo expansion of antigen-specific VSTs. The original and most widely used methodology for VST generation is stimulation and ex vivo culture to expand T-cells
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From targeting one or multiple viruses in a single product. Ex vivo expansion has several advantages over direct T-cell selection, including the generation of polyclonal T-cells, and the expansion of T-cells to clinically useful numbers from a small starting volume of blood. 16 These advantages may come at the expense of the required T-cell manufacture time, which can vary from 10 days to >3 months. Although T-cell exhaustion is a concern with the use of prolonged ex vivo culture and expansion methods, clinical trials utilizing gene-marked VSTs post-HCT have demonstrated long-term (>10 years) persistence of the cells. 31 Moreover, studies have shown that ex vivo culturing with virus-specific stimuli reduces alloreactivity in vitro, and any residual alloreactivity detected has not correlated with an increased risk of clinically significant GVHD. 32 Over the past few years, there have been a number of advances, including the availability of overlapping peptide pools as a source of antigen and the development of optimized vessels and culture conditions to rapidly expand T cells that have simplified this process while preserving viral specificity and optimal phenotype. 16, 17, 20 This is relevant as T cell products derived from CD62L+/CD45RA-central memory T-cells have superior persistence in vivo following adoptive transfer. 33 Another approach relied on selection on T cells specific for viral and fungal pathogens based on activation-dependent expression of CD154 which enabled generation of single-and multipathogen-specific T-cell lines in 14 days even if the precursor frequency was low. 34
(ii)
Direct selection of donor T cells. One rapid selection strategy is direct isolation of VSTs from donor peripheral blood using peptide-HLA multimers, which isolate T cells based on the ability of their receptor to bind to a complex of synthetic peptide-loaded recombinant HLA molecules. This process is restricted by HLA type and necessitates knowledge of which epitopes are immunodominant. The donor also needs to have a high frequency of T cells specific for the peptide used. Consequently, the broadest application of this approach has been for CMV and EBV, where the frequency of VSTs is usually high enough in seropositive
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From donors to enable selection. In addition, multimers are most readily made with class I HLA antigens, so the duration of an immune response following adoptive transfer may be limited in the absence of CD4+ T cells. Recently, researchers have evaluated streptamersmultimers in which HLA molecule-peptide and antigen-specific TCR binding is reversible by a competitor molecule that causes the streptamer to monomerize. 35 Streptamer selection has been used in a large European study, which has so far only been reported in abstract form. 36 An alternate strategy, IFNγ capture is based on secretion of IFNγ by VSTs after short-term stimulation with antigen; IFNγ secreting populations are then captured by labeling with an anti-IFNγ monoclonal antibody conjugated to a leukocyte-specific (CD45) antibody, followed by magnetic selection. This strategy selects both CD4+ and CD8+ antigen-specific T cells in an HLA unrestricted manner and has been used in trials to treat AdV, CMV and EBV infections in the post-HSCT setting. 23, 37, 38 Both of these direct selection strategies have the advantage of rapid manufacturing time, but also generally require the donor have an additional leukapheresis in order to collect sufficient cells for clinical use, which can be impractical in the unrelated donor setting.
Additionally, this approach necessitates that VSTs be readily detectable in the peripheral blood, and thus is not an option for virus-naïve donors or when trying to select T cells specific for pathogens that induce a poor memory response.
CLINICAL RESULTS WITH VSTS
Epstein Barr Virus
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From EBV is a ubiquitous human herpesvirus, and over 95% of the adult population is seropositive, After primary infection, the virus persists in latent form in B lymphocytes and epithelial cells in the nasopharynx, and periodic replicative reactivations in B cells are tightly controlled by a strong viral antigen-specific T-cell response such that up to 1-2% of circulating T cells in a normal EBV seropositive individual may be specific for EBV. 13 After HCT, EBV-infected B cells that would normally be controlled by an effective EBV-specific CTL response can outgrow, resulting in EBV PTLD. The risk of PTLD is higher in recipients who have received reduced intensity transplant conditioning regimens that include anti-thymocyte globulin (ATG) or alemtuzumab (Campath), a selectively T cell-depleted product or cord blood. PTLD developing after HCT is usually derived from donor B cells, but can be of recipient origin.
EBV is an excellent model for cellular immunotherapy since LCLs can be generated from any donor by infection of PBMC with the B95-8 laboratory strain, and LCLs are an excellent APC for stimulating EBV-specific T cells from EBV seropositive transplant donors (over 95% of cases). Rituximab-resistant disease. 39 While response rates have been high in these studies, evaluation of patients who failed to respond has also been informative. In one of the Baylor patients who had an initial response For personal use only. on October 4, 2017. by guest www.bloodjournal.org From then progressed, an EBV variant was found with a deletion in the immunodominant epitopes recognized by the infused line. 40 In the Sloan Kettering studies, another 3 patients who failed to respond received VSTs that also recognized the LCLs transformed with B-95 but not the strain of EBV expressed by the patients' tumor. 10 In another patient, the donor CTL line was skewed in its EBV response by an HLA antigen A1101, which was present only in the donor while the tumor was derived from recipient cells. The patient subsequently responded to a third-party line that was matched at fewer antigens but had strong EBV activity through a shared HLA antigen. 10 This experience illustrates the importance of ascertaining whether the PTLD is derived from donor or recipient cells. More recent studies have used peptides or EBNA-1 protein to stimulate VSTs that were then selected by gamma capture ( Table 3) . 23, 41 Although the numbers are small, the response rates appear similar.
Cytomegalovirus
CMV is a latent β -herpesvirus that can result in significant morbidity and mortality in patients post HCT. 42 As CMV-specific CD4+ and CD8+ T cells play an important role in immune protection from both primary infection and subsequent reactivations, several groups have investigated whether the adoptive transfer of in vitro expanded donor-derived VSTs can provide protection following HCT. Investigators in Seattle performed initial studies evaluating this approach 12,43 using fibroblasts infected with the AD169 strain of CMV to stimulate donor T cells, followed by cloning to isolate cytolytic CD8+ CMV-specific T cells for adoptive transfer. In a dose-escalation study, the CMV-specific clones were administered to recipients of matched sibling donor grafts and reconstituted CMV-specific CD8 + T-cell responses without inducing GVHD. 12 A number of studies from other centers using a variety of sources of antigen and APCs to generate polyclonal T cells have also shown excellent response rates ( Table 2) . 11, 44, 45 More recently, both multimer selection and gamma capture have also been used with high response rates 1, 22, 38 (Table 3) .
Adenovirus
ADV is also a significant cause of morbidity and mortality in HCT recipients. Many studies have targeted ADV in concert with other viruses (see below), but the Tubingen group has reported response rates of around 70% using the gamma capture strategy to select ADV-specific cells ( Table 3 ).
Multivirus VSTs
As HCT recipients who are immunosuppressed often develop multiple viral infections, several groups have explored the use of T cells targeting more than one virus ( Table 4 ). Our group developed a strategy to generate donor-derived T-cell lines recognizing CMV, EBV and adenovirus using an adenovirus vector expressing the CMVpp65 protein (Ad5f35-pp65) as a source of antigen and monocytes and EBV-LCLs as APCs. 24 The trivirus-specific T cell product produced immune reconstitution to CMV and EBV in all recipients and to adenovirus in patients with a reactivation or infection. Over 90% of patients with active infections or reactivations cleared the virus in association with an increase in VSTs in peripheral blood 24 (Table 4) . A similar approach was used by Blyth et al in a Phase 2 study where 40 allogeneic HCT recipients received donor-derived CMV and ADV-specific T cells stimulated with the same adenovirus-CMVpp65 vector as described above. 25 Of note, they compared outcomes with controls that did not receive T cells and saw no significant difference in the rate of CMV reactivation or GVHD, but did observe a significant reduction in the number of reactivations requiring pharmacotherapy and in the duration of such therapy in the VST group. 46 In more recent studies investigators have modified the source of antigen to stimulate donor
PBMCs and shown response rates were similar when using DNA plasmids encoding immunogenic antigens from EBV, CMV, and AdV introduced into APCs by nucleofection 25 or
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From using commercially available pepmixes consisting of 15mer peptide libraries derived from viral antigens that overlap by 11 amino acids 16 ( Table 4 ). The range of antigens has also been extended to include VZV, 47 BK, influenza 48 and HHV6. 28 In a study that extended the targeted viruses to five by adding HHV6 and BK, the infused VSTs produced a 94% virological and clinical response rate that was sustained long-term. 28 The only cause of failure was if the donor was seronegative for the infecting virus. 28
Alloreactivity
One initial concern with infusion of VSTs was the potential for alloreactivity either from residual alloreactive T cells in the product or from cross reactivity between viral and allo-antigens, since in vitro studies have shown that that a majority of VST lines possess cross-reactivity against allogeneic HLA molecules. 49 However, none of the published studies report an increased incidence of GVHD over what would be expected in the patient population even if the donor was mismatched 32 (Tables 2, 3 and 4) . Still the concern for alloreactivity has meant that most studies have excluded patients with GVHD of Grade II or greater. Moreover, many of these patients are on therapy with steroids, which are a contraindication to VST infusion due to their lytic effect on activated T cells. To address the unmet need in this population, who have a high incidence of viral infection, investigators have used gene editing to disrupt the glucocorticoid receptor gene using electroporation of transcription activator-like effector nucleases (TALEN) mRNA. Preclinical studies have shown this strategy renders streptamer-selected CMV-specific T cells resistant to glucocorticoids. 50 In other preclinical studies, genetic modification has rendered EBV-specific T cells resistant to calcineurin inhibitors. 51, 52 
THIRD-PARTY VST BANKS
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From Despite the high response rates seen with donor-derived VSTs, the need to generate a specific VST product for each patient means that this approach is not feasible for widespread or urgent use, and it is also challenging when the donor is seronegative. One approach to overcome these issues is to develop banks of HLA-matched VSTs from normal seropositive individuals so the most closely matched line with activity against the infecting virus through a shared antigen can be infused as an immediately available product when needed. There are potential risks with the use of third-party VSTs as most lines will be mismatched at one or more HLA-loci, which may result in shorter persistence after transfer thereby limiting the antiviral benefit due to recognition of alloantigens on the infused line by recipient cells. Conversely, alloreactivity of the line against recipient antigens may increase the risk of GVHD. While there is one report of bystander-induced liver GVHD after third-party ADV VSTs, 53 in general these concerns have been allayed by the published results ( Table 5 ). Results show that the strategy is feasible and does not induce a higher rate of GVHD than expected while producing significant responses.
The first reported study used banked EBV-specific VSTs to treat PTLD after solid organ or HSCT transplantation, matching VSTs by low resolution typing and screening for strong killing of donor LCLs in the absence of significant killing of patient-derived PHA blasts. [54] [55] [56] The response rates were 64% and 52% at 5 weeks and 6 months, respectively, and no GVHD was reported. 55 In a report from Sloan Kettering, 4 of 5 patients receiving third-party EBV-specific VSTs for PTLD developing after HCT had complete responses. 10, 57 Our group used banked third-party multivirus specific T cells to treat patients with refractory CMV, AdV, or EBV infections in a multicenter study. 58 We selected the infused VST line based on both the overall degree of HLA match but also on activity against the infecting virus through a shared HLA allele, which required analysis of viral epitopes and the HLA-restricting elements in the lines. We observed an overall cumulative incidence of CR/PR by day 42 of 74% with no significant difference between responses observed with each virus. 58 The overall response rates for third-party VSTs shown in Table 5 range from 50-70%, which is slightly lower than those observed with donor-derived For personal use only. on October 4, 2017. by guest www.bloodjournal.org From VSTs (Tables 2-4 ) but nevertheless encouraging. As the observed persistence is shorter than with donor-derived cells, multiple infusions may be required and more studies are needed to define attributes of the line associated with response and to determine the mechanism of action of the sustained clinical benefit.
MANUFACTURING T CELLS WITH VIRUS SPECIFICITY FROM VIRUS NAÏVE DONORS
The highest risk situation for viral reactivation/infection after HCT is when the donor is virus naïve and the recipient is already infected with the virus. Cord blood is an attractive donor source, especially for the pediatric population, but the T cell naivety does increase the risk for viral infection. Several groups have shown that VSTs can be primed in vitro from cord blood 59 and cord blood-derived T cells targeting CMV, EBV and AdV have been manufactured using a GMP compliant approach from the 20% fraction of cord blood units and administered to highrisk patients after CBT. 60 This approach used cord blood donor-derived DCs and LCLs as APCs, either transduced with the Ad5f35CMVpp65 vector or using viral pepmixes. 59 Interestingly, epitope mapping showed that the immunodominant CMVpp65 epitopes recognized by these T-cells differed from T-cells manufactured from CMV seropositive adult donors, but in a preliminary report still appeared to confer protection. 60 The same strategy is being evaluated clinically in seronegative adult donors.
The above experience and the success of the Berlin patient have stimulated interest in allogeneic VST therapy for the treatment of HIV. In a recent report, T cells specific for multiple HIV epitopes, irrespective of donor HLA type, were expanded from seronegative adult donors using DCs pulsed with pepmixes selected by a proprietary algorithm. These cells provided broad coverage across all HIV clades, and were stimulated with cytokines for initial priming, followed by restimulation with pepmix-pulsed cells. These T cells suppressed viral replication compared to unexpanded CD8+ T-cells and CMV-and EBV-specific T cells derived from the For personal use only. on October 4, 2017. by guest www.bloodjournal.org From same HIV-seronegative donors. HIV-specific T-cells manufactured this way are currently being evaluated in the autologous setting (NCT02208167) and studies utilizing donor-derived HIVspecific T cells after allogeneic HCT are planned. 61 An alternative approach in the naïve donor is to transduce T-cells with a TCR with known viral specificity. 62, 63 While this strategy offers a novel, rapid method to generate VSTs from naïve donors, it does impose the additional cost and regulatory requirements of gene transfer. In addition, the strategy is HLA restricted and targeting a single viral epitope increases the risk of viral immune escape. However, a clinical trial is currently underway in the United Kingdom evaluating T cells transduced with a retroviral vector expressing a CMV-specific TCR for highrisk patients after HCT (Morris E. et al, http://gtr.rcuk.ac.uk/projects?ref=G0701703).
FUTURE DIRECTIONS AND CONCLUSIONS
In summary, the adoptive transfer of VSTs can restore antiviral immunity and treat viral infections in many patients who fail to respond to conventional therapies after HCT. HCT recipients with active disease who receive VSTs in a donor-specific setting have response rates between 70-90%, and even in the third-party setting response rates approach 70%. Given that, in the majority of cases, responses are durable with a minimal toxicity profile, this strategy has many advantages compared with pharmacologic therapies and its broader application is made increasingly possible due to third-party VST banks and rapid manufacture methodologies. Latephase licensing studies are now in progress evaluating infusion of VSTs post HCT and it will be important to incorporate cost and quality of life analyses in these trials. Future directions include devising strategies that can be used in patients who have viral infection with active GVHD and who are receiving steroids and immunosuppressive agents. [50] [51] [52] Infusions of VSTs genetically modified with chimeric antigen receptors 64 can also be used after strategies to reduce GVHD such as naïve cell depletion, 6 TCR alpha beta depletion 65 or CD34 selection 7 with the goal of For personal use only. on October 4, 2017. by guest www.bloodjournal.org From both preventing GVHD and promoting antiviral and anti-tumor immunity. In addition, exploring strategies to enhance virus-specific activity in naïve donor-derived T cells will further broaden applicability to some of the highest risk patients after HCT, and the manufacture of T cells specific for an increasing number of viruses including HIV, respiratory viruses and HPV 66 For personal use only. on October 4, 2017. by guest www.bloodjournal.org From
